SCHEMBL491496

SCHEMBL491496

CC(=O)CC(=O)OC(CO)CO

nearest known ligand 0.50

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
MGAM O43451 1/20 0.50
GAA P10253 1/20 0.50
SI P14410 1/20 0.50
MGAM2 Q2M2H8 1/20 0.50
MAPT P10636 2/20 0.48
MAPK1 P28482 1/20 0.48
PRKCA P17252 6/20 0.40
FAAH O00519 1/20 0.39
ALDH1A1 P00352 1/20 0.39
HPGD P15428 1/20 0.39
CNR1 P21554 1/20 0.39
CNR2 P34972 1/20 0.39
PRKCE Q02156 1/20 0.38
PRKCQ Q04759 1/20 0.38
PRKCD Q05655 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL491474 0.86 PRKCA (0.54) PRKCAPRKCEPRKCQPRKCD
SCHEMBL2568907 0.85 MAPT (0.50) MGAMGAASIMGAM2MAPT
SCHEMBL12199528 0.81 MAPT (0.48) MGAMGAASIMGAM2MAPT
SCHEMBL7321395 0.81 MGAM (0.50) MGAMGAASIMGAM2MAPT
SCHEMBL18026483 0.79 MGAM (0.48) MGAMGAASIMGAM2MAPT
SCHEMBL402501 0.79 MAPT (0.57) MAPTMAPK1PRKCAFAAHALDH1A1
SCHEMBL11328900 0.78 MGAM (0.35) MGAMGAASIMGAM2MAPT
SCHEMBL22124620 0.78 MAPT (0.45) MAPTMAPK1PRKCAFAAHALDH1A1
SCHEMBL648594 0.77 ALDH1A1 (0.47) MGAMGAASIMGAM2PRKCA
SCHEMBL11125832 0.77 PRKCA (0.38) MAPTMAPK1PRKCAPRKCEPRKCQ

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 135 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11890264-B2 Migraine prevention and treatment UNIVERSITATS-KINDERSPITAL BEIDER BASEL (CH) 2024-02-06 US claimed
US-20210338618-A1 MIGRAINE PREVENTION AND TREATMENT UNIVERSITATS-KINDERSPITAL BEIDER BASEL (CH) 2021-11-04 US claimed
US-20250275986-A1 COMBINATION OF A KETONE BODY OR KETOGENIC COMPOUND WITH AN ANALGESIC OR ANTIOXIDANT KETOSWISS AG (CH) 2025-09-04 US disclosed
US-12286534-B2 Binder for an aqueous coating composition ALLNEX AUSTRIA GMBH (AT) 2025-04-29 US disclosed
US-20240425643-A1 FOAM COMPOSITIONS AMRIZE TECHNOLOGY SWITZERLAND LLC (CH) 2024-12-26 US disclosed
US-12098240-B2 Foam compositions HOLCIM TECHNOLOGY LTD (CH) 2024-09-24 US disclosed
US-12071498-B2 Radically polymerizable compositions Polynt Composites USA, Inc. (US) 2024-08-27 US disclosed
EP-4373483-A1 COMBINATION OF A KETONE BODY OR KETOGENIC COMPOUND WITH AN ANALGESIC OR ANTIOXIDANT KetoSwiss AG (CH) 2024-05-29 EP disclosed
CN-117677383-A Combinations of ketone bodies or ketone-forming compounds, analgesics or antioxidants 瑞士凯托股份公司 2024-03-08 CN disclosed
US-11890264-B2 Migraine prevention and treatment UNIVERSITATS-KINDERSPITAL BEIDER BASEL (CH) 2024-02-06 US disclosed
CN-113474383-B Free radical polymerizable composition 波林复合材料美国股份有限公司 2023-10-31 CN disclosed
WO-2004091665-A1 COMBINATION THERAPY FOR CONSTIPATION COMPRISING A LAXATIVE AND A PERIPHERAL OPIOID ANTAGONIST PROGENICS PHARMACEUTICALS, INC. (US) 2004-10-28 WO disclosed
US-4970143-A BICARBONATE BUFFER SOLUTION NESTEC S.A. (CH) 1990-11-13 US disclosed
EP-0184905-B1 2-ACETOACETYLGLYCEROL DERIVATIVES, THEIR PRODUCTION AND USE Takeda Chemical Industries, Ltd. (JP) 1989-03-01 EP disclosed
US-4710579-A ANTITUMOR AGENTS TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1987-12-01 US disclosed
EP-0184905-A1 2-Acetoacetylglycerol derivatives, their production and use Takeda Chemical Industries, Ltd. (JP) 1986-06-18 EP disclosed
EP-0184905-A1 2-Acetoacetylglycerol derivatives, their production and use Takeda Chemical Industries, Ltd. (JP) 1986-06-18 EP disclosed
EP-0037943-B1 PHARMACEUTICAL COMPOSITION FOR INTRARECTAL ADMINISTRATION, AND SUPPOSITORY PREPARED THEREFROM TEIJIN LIMITED (JP) 1985-08-14 EP disclosed
US-4434159-A PEPTIDE HORMONES, POLYSACCHARIDES, ABSORPTION AIDS TEIJIN LIMITED (JP) 1984-02-28 US disclosed
EP-0037943-A2 Pharmaceutical composition for intrarectal administration, and suppository prepared therefrom TEIJIN LIMITED (JP) 1981-10-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210338618-A1 MIGRAINE PREVENTION AND TREATMENT ACACA, ACACB, HBB MGAM 2155/4885GAA 751/4885SI 906/4885
US-11890264-B2 Migraine prevention and treatment ACACA, ACACB, HBB MGAM 2155/4885GAA 751/4885SI 906/4885
US-20250275986-A1 COMBINATION OF A KETONE BODY OR KETOGENIC COMPOUND WITH AN ANALGESIC OR ANTIOXIDANT PKM, KCNMA1, KCNK18 MGAM 497/4885GAA 2246/4885SI 1007/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.